Media releases Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 23 December 2019 Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy more Published on: 19 December 2019 European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment more Published on: 17 December 2019 Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy more Published on: 17 December 2019 Roche purchases shares in tender offer for Spark Therapeutics, Inc. more Published on: 16 December 2019 Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc more Published on: 16 December 2019 Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority more Published on: 13 December 2019 Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma more Published on: 12 December 2019 Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer more Published on: 11 December 2019 APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen more Published on: 10 December 2019 Roche receives CE Mark for its Accu-Chek SugarView app more Published on: 9 December 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 more Published on: 9 December 2019 Changes in the Board of Directors and the Corporate Executive Committee of Roche more Published on: 8 December 2019 New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia more Published on: 4 December 2019 FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer more Published on: 2 December 2019 Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine more Published on: 25 November 2019 FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy more Published on: 22 November 2019 Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer more Published on: 22 November 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 18 November 2019 Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium more Published on: 15 November 2019 CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment more Published on: 15 November 2019 CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma more Published on: 11 November 2019 Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone more Published on: 11 November 2019 Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy more Published on: 6 November 2019 Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting more Published on: 30 October 2019 Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA more Published on: 29 October 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 21 October 2019 Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma more Published on: 18 October 2019 Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications more Published on: 16 October 2019 Roche reports very strong sales growth in the first nine months of 2019 – outlook raised more Published on: 14 October 2019 Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris more Published on: 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer more Published on: 30 September 2019 Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa more Published on: 30 September 2019 FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders more Published on: 30 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 28 September 2019 Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer more Published on: 27 September 2019 Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer more Published on: 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma more Published on: 23 September 2019 Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress more Published on: 20 September 2019 FDA approves cobas Babesia, Roche’s first whole blood test for donor screening more Published on: 19 September 2019 Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary more Published on: 18 September 2019 FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis more Published on: 16 September 2019 Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running more Published on: 16 September 2019 Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients more Published on: 13 September 2019 Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis more Published on: 13 September 2019 Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer more Published on: 12 September 2019 Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum more Published on: 12 September 2019 Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy more Published on: 10 September 2019 Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS more Published on: 6 September 2019 European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer more Published on: 6 September 2019 European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer more Published on: 4 September 2019 Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS more Published on: 3 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 2 September 2019 Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% more Published on: 2 September 2019 Roche presents positive phase III study results for one-dose Xofluza in children with flu more Published on: 29 August 2019 Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq more Published on: 29 August 2019 European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer more Published on: 16 August 2019 FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours more Published on: 5 August 2019 Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer more Published on: 31 July 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 26 July 2019 Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer more Published on: 26 July 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer more Published on: 25 July 2019 Roche reports very strong performance in the first half of 2019 – Outlook raised more Published on: 22 July 2019 Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus more Published on: 9 July 2019 Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress more Published on: 28 June 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer more Published on: 18 June 2019 Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek more Published on: 11 June 2019 FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma more Published on: 11 June 2019 Changes in Roche's Board of Directors and Corporate Executive Committee more Published on: 10 June 2019 Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 4 June 2019 Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine more Published on: 3 June 2019 Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 2 June 2019 Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases more Published on: 31 May 2019 Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care more Published on: 16 May 2019 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia more Published on: 16 May 2019 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents more Published on: 14 May 2019 New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths more Published on: 14 May 2019 Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 10 May 2019 Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 8 May 2019 Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting more Published on: 7 May 2019 Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting more Published on: 6 May 2019 FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment more Published on: 29 April 2019 New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio more Published on: 26 April 2019 Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 23 April 2019 Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy more Published on: 17 April 2019 Roche reports a strong start in 2019 and raises the outlook for the full-year more Published on: 3 April 2019 Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. more Published on: 1 April 2019 Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial more Published on: 19 March 2019 FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer more Published on: 15 March 2019 European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease more Published on: 14 March 2019 European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors more Published on: 11 March 2019 Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane more Published on: 11 March 2019 FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer more Published on: 8 March 2019 European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer more Published on: 7 March 2019 Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash more Published on: 7 March 2019 Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions more Published on: 5 March 2019 Roche Annual General Meeting 2019 more Published on: 28 February 2019 FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers more Published on: 25 February 2019 Roche enters into definitive merger agreement to acquire Spark Therapeutics more Published on: 19 February 2019 FDA grants Priority Review to Roche’s personalised medicine entrectinib more Published on: 19 February 2019 FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma more Published on: 6 February 2019 Roche joins the World Federation of Hemophilia Humanitarian Aid Program more Published on: 5 February 2019 Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment more Published on: 1 February 2019 CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors more Published on: 1 February 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer more Published on: 31 January 2019 Roche reports very strong results in 2018 more Published on: 30 January 2019 Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) - other company programmes in AD continue more Published on: 17 January 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer more
Published on: 23 December 2019 Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy more
Published on: 19 December 2019 European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment more
Published on: 17 December 2019 Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy more
Published on: 17 December 2019 Roche purchases shares in tender offer for Spark Therapeutics, Inc. more
Published on: 16 December 2019 Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc more
Published on: 16 December 2019 Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority more
Published on: 13 December 2019 Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma more
Published on: 12 December 2019 Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer more
Published on: 11 December 2019 APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen more
Published on: 9 December 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 more
Published on: 9 December 2019 Changes in the Board of Directors and the Corporate Executive Committee of Roche more
Published on: 8 December 2019 New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia more
Published on: 4 December 2019 FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer more
Published on: 2 December 2019 Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine more
Published on: 25 November 2019 FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy more
Published on: 22 November 2019 Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer more
Published on: 22 November 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 18 November 2019 Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium more
Published on: 15 November 2019 CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment more
Published on: 15 November 2019 CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma more
Published on: 11 November 2019 Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone more
Published on: 11 November 2019 Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy more
Published on: 6 November 2019 Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting more
Published on: 30 October 2019 Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA more
Published on: 29 October 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 21 October 2019 Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma more
Published on: 18 October 2019 Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications more
Published on: 16 October 2019 Roche reports very strong sales growth in the first nine months of 2019 – outlook raised more
Published on: 14 October 2019 Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris more
Published on: 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer more
Published on: 30 September 2019 Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa more
Published on: 30 September 2019 FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders more
Published on: 30 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 28 September 2019 Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer more
Published on: 27 September 2019 Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer more
Published on: 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma more
Published on: 23 September 2019 Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress more
Published on: 20 September 2019 FDA approves cobas Babesia, Roche’s first whole blood test for donor screening more
Published on: 19 September 2019 Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary more
Published on: 18 September 2019 FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis more
Published on: 16 September 2019 Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running more
Published on: 16 September 2019 Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients more
Published on: 13 September 2019 Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis more
Published on: 13 September 2019 Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer more
Published on: 12 September 2019 Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum more
Published on: 12 September 2019 Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy more
Published on: 10 September 2019 Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS more
Published on: 6 September 2019 European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer more
Published on: 6 September 2019 European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer more
Published on: 4 September 2019 Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS more
Published on: 3 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 2 September 2019 Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% more
Published on: 2 September 2019 Roche presents positive phase III study results for one-dose Xofluza in children with flu more
Published on: 29 August 2019 Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq more
Published on: 29 August 2019 European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer more
Published on: 16 August 2019 FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours more
Published on: 5 August 2019 Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer more
Published on: 31 July 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 26 July 2019 Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer more
Published on: 26 July 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer more
Published on: 25 July 2019 Roche reports very strong performance in the first half of 2019 – Outlook raised more
Published on: 22 July 2019 Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus more
Published on: 9 July 2019 Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress more
Published on: 28 June 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer more
Published on: 18 June 2019 Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek more
Published on: 11 June 2019 FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma more
Published on: 11 June 2019 Changes in Roche's Board of Directors and Corporate Executive Committee more
Published on: 10 June 2019 Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 4 June 2019 Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine more
Published on: 3 June 2019 Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 2 June 2019 Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases more
Published on: 31 May 2019 Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care more
Published on: 16 May 2019 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia more
Published on: 16 May 2019 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents more
Published on: 14 May 2019 New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths more
Published on: 14 May 2019 Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 10 May 2019 Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 8 May 2019 Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting more
Published on: 7 May 2019 Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting more
Published on: 6 May 2019 FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment more
Published on: 29 April 2019 New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio more
Published on: 26 April 2019 Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 23 April 2019 Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy more
Published on: 17 April 2019 Roche reports a strong start in 2019 and raises the outlook for the full-year more
Published on: 3 April 2019 Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. more
Published on: 1 April 2019 Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial more
Published on: 19 March 2019 FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer more
Published on: 15 March 2019 European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease more
Published on: 14 March 2019 European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors more
Published on: 11 March 2019 Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane more
Published on: 11 March 2019 FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer more
Published on: 8 March 2019 European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer more
Published on: 7 March 2019 Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash more
Published on: 7 March 2019 Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions more
Published on: 28 February 2019 FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers more
Published on: 25 February 2019 Roche enters into definitive merger agreement to acquire Spark Therapeutics more
Published on: 19 February 2019 FDA grants Priority Review to Roche’s personalised medicine entrectinib more
Published on: 19 February 2019 FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma more
Published on: 6 February 2019 Roche joins the World Federation of Hemophilia Humanitarian Aid Program more
Published on: 5 February 2019 Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment more
Published on: 1 February 2019 CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors more
Published on: 1 February 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer more
Published on: 30 January 2019 Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) - other company programmes in AD continue more
Published on: 17 January 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer more